14-3-3γ Protects Against Postoperative Cognitive Dysfunction by Regulating Tau Thr205 Phosphorylation and Synaptic Integrity.

Summary

CSF proteomics identified 14-3-3γ as a candidate biomarker associated with neurodegenerative cognitive vulnerability, and plasma levels were associated with postoperative cognitive dysfunction and postoperative delirium. In mice, surgery and anesthesia reduced hippocampal 14-3-3γ, increased Tau Thr205 phosphorylation, impaired synaptic function, and worsened cognition; overexpression or pharmacological stabilization of the 14-3-3γ–Tau interaction reversed these abnormalities.

Key Findings

• CSF proteomics identified 14-3-3γ as a biomarker associated with neurodegeneration-enriched cognitive vulnerability.
• Plasma 14-3-3γ levels were associated with postoperative cognitive dysfunction and postoperative delirium in a prospective surgical cohort.
• In mice, 14-3-3γ overexpression or pharmacological stabilization of its interaction with Tau reduced Tau Thr205 phosphorylation, restored synaptic function, and improved cognition.

Clinical Implications

Circulating 14-3-3γ may eventually support perioperative cognitive-risk stratification, although it is not ready for clinical use. The 14-3-3γ–Tau interaction provides a rationale for future targeted therapies to prevent or treat postoperative cognitive dysfunction and delirium.

Limitations

• The human cohorts establish associations but cannot definitively prove that 14-3-3γ changes cause postoperative cognitive dysfunction.
• The therapeutic experiments were conducted in mice and neuronal models, so human efficacy, dosing, and safety remain unestablished.

Future Directions

Prospective multicenter studies should validate 14-3-3γ as a perioperative biomarker, define its relationship with delirium and long-term cognitive decline, and test 14-3-3γ–Tau stabilizers in translational safety and efficacy studies.